Renal artery denervation: a lot done and more to do

EuroIntervention 2018;14:e1252-e1254. DOI: 10.4244/EIJV14I12A225

Faisal Sharif
Faisal Sharif1,2,3,4*, MBBS, PhD, FESC, FRCPI, FACC
1. Department of Cardiology, University Hospital Galway, Galway, Ireland; 2. BioInnovate Ireland, Galway, Ireland; 3. Cardiovascular Research and Innovation Centre Ireland, School of Medicine, National University of Ireland Galway, Galway, Ireland; 4. CÚRAM-SFI Centre for Research in Medical Devices, Galway, Ireland

Few therapies for hypertension have had such a roller-coaster ride as renal artery denervation (RDN). Early optimism was enormous when trials reported reductions in systolic blood pressure (SBP) of >20 mmHg in patients resistant to standard pharmacotherapy. Yet euphoria turned to something close to despair when, later, rigorously designed trials failed to repeat the results. Recently, the therapy seems to have bounced back from its near-death experience. A series of trials have reported positive results and research has been revived. What are we to make of it all?

The unmet need is undisputed: hypertension is the most important ...

Sign in to read and download the full article

Forgot your password?

No account yet?
Sign up for free!

Create my pcr account

Join us for free and access thousands of articles from EuroIntervention, as well as presentations, videos, cases from PCRonline.com

Read next article
Continuous development of neoatherosclerosis beyond a decade after drug-eluting stent implantation

Latest news